Patent number: JP2001516214T Publication date: 2001-09-25

Inventor: Applicant: Classification:

- international:

C12N15/09: A61K39/395: A61P7/02: A61P9/00: C07K16/28: C07K16/36: C07K16/46: C12N1/15: C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12P21/08: C12Q1/68: A61K38/00: C12N15/09: A61K39/395; A61P7/00; A61P9/00; C07K16/18; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12P21/08; C12Q1/68; A61K38/00; (IPC1-7); C12N15/09; A61K39/395; A61P7/02: A61P9/00: C07K16/28: C07K16/46:

C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/08: C12Q1/68 - european: C07K16/36: A61K39/395

Priority number(s): US19970814806 19970310; WO1998US04644

Application number: JP19980539703T 19980310 19980310

Also published as: WO9840408 (A1)

EP0975672 (A1) US6555319 (B2) US5986065 (A1) US2002168357 (A1)

more >>

Report a data error here

Abstract not available for JP2001516214T Abstract of correspondent: WO9840408

The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF: VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.

Data supplied from the esp@cenet database - Worldwide